From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Aptamer – having argued in January “good visibility on its commercial pipeline”... now a calamitous “trading update”! ANOTHER covid-era AIM IPO Roll-Call of Shame

By Steve Moore | Friday 5 May 2023

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

Writing on ‘novel optimer binders to enable innovation in the life sciences industry’ group Aptamer (APTA) in January with the shares down to 47.5p, as it argued “good visibility on its commercial pipeline going into the second half” I questioned that and concluded for the business and macro conditions, avoid / sell. Today a trading update… and the shares currently further down to 13p!

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Filed under:

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

Time left: 07:41:52